Antibe Therapeutics Inc(Pre-Merger) T.ATE

Alternate Symbol(s): ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

TSX:ATE - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Webinar for tmrrw

<< Previous

Bullboard Posts

Next >>

Comment by YukonJezzaon Aug 12, 2021 3:15am

166 Views

Post# 33690206

RE:RE:RE:RE:RE:Webinar for tmrrw

YukonJezza wrote:
MrMugsy wrote:
themagicbox wrote: MUGS, what are you thoughts on the 352 and 340 at this point?

I'm thinking based on the corp letter and the recent event with Otena, they'll probably focus on creating new compounds for those indications that 352 and 340 target to extend patents.

Yes ... we've been tipped off with some clues on new strategy for 352 as it has become an extended IP project.

Check your private messaging ... I can give you my rendition of how I see it unfolding.

Mugs, I can't help myself. Did your rendition see this drop 70%? How little you know. Dude you don't even own shares. Your not even phased. Nothing. I compare you to Duster. You are the same game.